Literature DB >> 31577958

Phosphoethanolamine Accumulation Protects Cancer Cells under Glutamine Starvation through Downregulation of PCYT2.

Tsuyoshi Osawa1, Teppei Shimamura2, Kyoko Saito3, Yoko Hasegawa4, Naoko Ishii4, Miyuki Nishida4, Ritsuko Ando4, Ayano Kondo5, Muyassar Anwar5, Rika Tsuchida4, Shinjiro Hino6, Akihisa Sakamoto6, Kaori Igarashi7, Kaori Saitoh7, Keiko Kato7, Keiko Endo7, Shotaro Yamano8, Yasuharu Kanki9, Yoshihiro Matsumura10, Takashi Minami11, Toshiya Tanaka12, Motonobu Anai12, Youichiro Wada9, Hideki Wanibuchi8, Mitsuhiro Hayashi13, Akinobu Hamada14, Masayuki Yoshida15, Shinichi Yachida16, Mitsuyoshi Nakao6, Juro Sakai17, Hiroyuki Aburatani5, Masabumi Shibuya18, Kentaro Hanada3, Satoru Miyano19, Tomoyoshi Soga20, Tatsuhiko Kodama21.   

Abstract

Tolerance to severe tumor microenvironments, including hypoxia and nutrient starvation, is a common feature of aggressive cancer cells and can be targeted. However, metabolic alterations that support cancer cells upon nutrient starvation are not well understood. Here, by comprehensive metabolome analyses, we show that glutamine deprivation leads to phosphoethanolamine (PEtn) accumulation in cancer cells via the downregulation of PEtn cytidylyltransferase (PCYT2), a rate-limiting enzyme of phosphatidylethanolamine biosynthesis. PEtn accumulation correlated with tumor growth under nutrient starvation. PCYT2 suppression was partially mediated by downregulation of the transcription factor ELF3. Furthermore, PCYT2 overexpression reduced PEtn levels and tumor growth. In addition, PEtn accumulation and PCYT2 downregulation in human breast tumors correlated with poor prognosis. Thus, we show that glutamine deprivation leads to tumor progression by regulating PE biosynthesis via the ELF3-PCYT2 axis. Furthermore, manipulating glutamine-responsive genes could be a therapeutic approach to limit cancer progression.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PCYT2; PE biosynthesis; amino acids; cancer metabolism; glutamine deprivation; hypoxia; nutrient starvation; phosphoethanolamine; tumor microenvironments

Year:  2019        PMID: 31577958     DOI: 10.1016/j.celrep.2019.08.087

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  13 in total

1.  Atg6 promotes organismal health by suppression of cell stress and inflammation.

Authors:  James L Shen; Johnna Doherty; Elizabeth Allen; Tina M Fortier; Eric H Baehrecke
Journal:  Cell Death Differ       Date:  2022-05-06       Impact factor: 15.828

2.  Metabolomic analysis of endometrial cancer by high-resolution magic angle spinning NMR spectroscopy.

Authors:  Senem Arda Düz; Akın Mumcu; Berat Doğan; Ercan Yılmaz; Ebru İnci Çoşkun; Erdinç Sarıdogan; Görkem Tuncay; Abdullah Karaer
Journal:  Arch Gynecol Obstet       Date:  2022-05-14       Impact factor: 2.344

3.  In vivo spectral editing of phosphorylethanolamine.

Authors:  Steve C N Hui; Helge J Zöllner; Georg Oeltzschner; Richard A E Edden; Muhammad G Saleh
Journal:  Magn Reson Med       Date:  2021-08-19       Impact factor: 4.668

4.  Expression of the Human Serotonin 5-HT7 Receptor Rescues Phenotype Profile and Restores Dysregulated Biomarkers in a Drosophila melanogaster Glioma Model.

Authors:  Florestan Courant; Marion Maravat; Wanyin Chen; David Gosset; Lauren Blot; Nadège Hervouet-Coste; Vincent Sarou-Kanian; Séverine Morisset-Lopez; Martine Decoville
Journal:  Cells       Date:  2022-04-09       Impact factor: 7.666

5.  Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma.

Authors:  Kenji Fujimoto; Naoki Shinojima; Mitsuhiro Hayashi; Tomoyuki Nakano; Koichi Ichimura; Akitake Mukasa
Journal:  Neurooncol Adv       Date:  2020-07-03

6.  The Functional Impact of Alternative Splicing on the Survival Prognosis of Triple-Negative Breast Cancer.

Authors:  Sijia Wu; Jiachen Wang; Xinchao Zhu; Jacqueline Chyr; Xiaobo Zhou; Xiaoming Wu; Liyu Huang
Journal:  Front Genet       Date:  2021-01-14       Impact factor: 4.599

Review 7.  Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis.

Authors:  Kenji Ohshima; Eiichi Morii
Journal:  Metabolites       Date:  2021-01-02

8.  Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer.

Authors:  Leticia Díaz-Beltrán; Carmen González-Olmedo; Natalia Luque-Caro; Caridad Díaz; Ariadna Martín-Blázquez; Mónica Fernández-Navarro; Ana Laura Ortega-Granados; Fernando Gálvez-Montosa; Francisca Vicente; José Pérez Del Palacio; Pedro Sánchez-Rovira
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639

9.  Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach.

Authors:  Caridad Díaz; Carmen González-Olmedo; Leticia Díaz-Beltrán; José Camacho; Patricia Mena García; Ariadna Martín-Blázquez; Mónica Fernández-Navarro; Ana Laura Ortega-Granados; Fernando Gálvez-Montosa; Juan Antonio Marchal; Francisca Vicente; José Pérez Del Palacio; Pedro Sánchez-Rovira
Journal:  Mol Oncol       Date:  2022-04-14       Impact factor: 7.449

10.  Identification of Breast Cancer Subtype-Specific Biomarkers by Integrating Copy Number Alterations and Gene Expression Profiles.

Authors:  Claudia Cava; Mirko Pisati; Marco Frasca; Isabella Castiglioni
Journal:  Medicina (Kaunas)       Date:  2021-03-12       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.